Business Context and Reporting Period
Zenas BioPharma, Inc. (ZBIO) is a clinical-stage biopharmaceutical company focused on developing immunology and inflammation (I&I) therapies. The reporting period covers the fiscal year ended December 31, 2025. The company has no approved products and generates revenue solely from license and collaboration agreements. Its lead asset, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to inhibit B-cell activity without depletion. The company also holds rights to orelabrutinib (a BTK inhibitor) and early-stage candidates ZB021 and ZB022.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $10.0 million | $5.0 million |
| Net Loss | $(377.7) million | $(157.0) million |
| Operating Expenses | $393.1 million | $168.9 million |
| Research & Development (R&D) | $168.1 million | $139.1 million |
| General & Administrative (G&A) | $53.3 million | $29.7 million |
| Acquired IPR&D Expense | $171.7 million | $0 |
| Cash, Cash Equivalents & Investments (Dec 31, 2025) | $360.5 million | $350.8 million |
| Accumulated Deficit (Dec 31, 2025) | $(765.1) million | $(387.4) million |
Material Changes vs. Prior Period
- Revenue Increase: Revenue doubled to $10.0 million, driven by a $10.0 million upfront payment from the Zai License Agreement for ZB001 in greater China.
- Significant Expense Growth: Total operating expenses increased by $224.2 million. This was primarily due to a one-time $171.7 million charge for acquired in-process research and development (IPR&D) related to the InnoCare License Agreement (cash and stock consideration for orelabrutinib, ZB021, and ZB022).
- R&D Spend: R&D expenses rose $28.9 million, driven by increased clinical trial costs for obexelimab and the initiation of orelabrutinib development.
- Net Loss Expansion: Net loss more than doubled to $377.7 million, reflecting the non-cash IPR&D charge and increased operational costs.
Guidance, Outlook, and Risks
Clinical Milestones and Outlook
- Obexelimab (IgG4-RD): Reported positive Phase 3 INDIGO trial results in January 2026 (56% reduction in flare risk). Plans to submit a Biologics License Application (BLA) to the FDA in Q2 2026 and a Marketing Authorization Application (MAA) to the EMA in H2 2026.
- Obexelimab (MS): Reported positive Phase 2 MoonStone trial results (95% reduction in new lesions). 24-week data confirmed durability. Next steps for development are under evaluation.
- Obexelimab (SLE): Phase 2 SunStone trial ongoing; topline results expected in Q4 2026.
- Orelabrutinib: Phase 3 PriMroSe trial in Primary Progressive MS (PPMS) initiated in September 2025. A second Phase 3 trial in non-active Secondary Progressive MS (SPMS) is planned for initiation in Q1 2026.
Liquidity and Going Concern
Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least 12 months following the filing date. While the company had $360.5 million in cash and investments as of December 31, 2025, and secured a $75.0 million tranche of a $250.0 million term loan facility in March 2026, management projects these resources will fund operations for approximately 12 months. Additional financing will be required to achieve commercialization goals.
Key Risks
- Capital Requirements: Failure to secure additional financing could force delays or termination of product development.
- Regulatory Approval: No products are approved; clinical success does not guarantee regulatory approval.
- Supply Chain: Reliance on single-source manufacturers in China (WuXi Biologics for obexelimab, InnoCare for orelabrutinib) exposes the company to geopolitical and trade risks, including potential impacts from the BIOSECURE Act.
- Competition: Intense competition in I&I indications, including recent FDA approval of Uplizna for IgG4-RD.
Investor Verification Checklist
- Going Concern Status: Verify the sufficiency of the $360.5 million cash balance plus the $75 million loan tranche against the projected 12-month runway and the auditor's "substantial doubt" qualification.
- BLA Submission Timeline: Confirm the Q2 2026 FDA BLA submission for obexelimab in IgG4-RD following the positive INDIGO trial data.
- InnoCare Deal Economics: Review the $171.7 million IPR&D charge and the remaining contingent milestone obligations (up to $723 million for orelabrutinib) under the InnoCare License Agreement.
- Debt Covenants: Examine the terms of the March 2026 Loan Agreement with Pharmakon, specifically the minimum liquidity covenants and the requirement to meet the "Tranche B/C Approval Condition" (FDA approval) to access future tranches.
- Manufacturing Risks: Assess the company's progress in qualifying U.S.-based alternative CMOs to mitigate reliance on Chinese suppliers (WuXi Biologics/InnoCare) amidst geopolitical tensions.